Zoryve is under clinical development by Arcutis Biotherapeutics and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zoryve’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zoryve overview

Roflumilast (Zoryve) is a long-acting selective phosphodiesterase 4 (PDE4) inhibitor. It is formulated as foam for topical application. Zoryve is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

ARQ-154 is under development for the treatment of scalp psoriasis and plaque psoriasis.The drug candidate is formulated as a foam and administered by topical route. It acts by targeting phosphodiesterase 4 (PDE4).

Arcutis Biotherapeutics overview

Arcutis Biotherapeutics (Arcutis) is a biopharmaceutical company. It is in developing small molecules for the treatment of immune-mediated dermatological diseases and conditions. Its pipeline products include a topical roflumilast cream, ARQ-252, a small molecule inhibitor of Janus kinase type 1 (JAK1) to treat rheumatoid arthritis, psoriasis, Crohn’s disease and atopic dermatitis and ARQ-255 for inflammation in alopecia areata. Arcutis other pipeline includes ARQ 252 for the treatment of chronic hand eczema.The company also investigating novel dermatology treatments in inflammation and immunology diseases. Arcutis is headquartered in Westlake Village, California, the US.

For a complete picture of Zoryve’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.